161 related articles for article (PubMed ID: 28988508)
1. Immunological effects of everolimus in patients with metastatic renal cell cancer.
Huijts CM; Santegoets SJ; de Jong TD; Verheul HM; de Gruijl TD; van der Vliet HJ
Int J Immunopathol Pharmacol; 2017 Dec; 30(4):341-352. PubMed ID: 28988508
[TBL] [Abstract][Full Text] [Related]
2. The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial.
Huijts CM; Lougheed SM; Bodalal Z; van Herpen CM; Hamberg P; Tascilar M; Haanen JB; Verheul HM; de Gruijl TD; van der Vliet HJ;
Cancer Immunol Immunother; 2019 Mar; 68(3):503-515. PubMed ID: 30652208
[TBL] [Abstract][Full Text] [Related]
3. Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.
Huijts CM; Santegoets SJ; van den Eertwegh AJ; Pijpers LS; Haanen JB; de Gruijl TD; Verheul HM; van der Vliet HJ
BMC Cancer; 2011 Nov; 11():505. PubMed ID: 22129044
[TBL] [Abstract][Full Text] [Related]
4. Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus.
Werter IM; Huijts CM; Lougheed SM; Hamberg P; Polee MB; Tascilar M; Los M; Haanen JBAG; Helgason HH; Verheul HM; de Gruijl TD; van der Vliet HJ;
Cancer Immunol Immunother; 2019 May; 68(5):787-798. PubMed ID: 30756132
[TBL] [Abstract][Full Text] [Related]
5. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.
van der Vliet HJ; Koon HB; Yue SC; Uzunparmak B; Seery V; Gavin MA; Rudensky AY; Atkins MB; Balk SP; Exley MA
Clin Cancer Res; 2007 Apr; 13(7):2100-8. PubMed ID: 17404092
[TBL] [Abstract][Full Text] [Related]
6. Different immunological effects of the molecular targeted agents sunitinib, everolimus and temsirolimus in patients with renal cell carcinoma.
Kobayashi Y; Yamada D; Kawai T; Sato Y; Teshima T; Yamada Y; Nakamura M; Suzuki M; Matsumoto A; Nakagawa T; Hosoi A; Nagaoka K; Karasaki T; Matsushita H; Kume H; Kakimi K
Int J Oncol; 2020 Apr; 56(4):999-1013. PubMed ID: 32319571
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory effects of everolimus in a long responsive patient with metastatic renal cell carcinoma.
Thiery-Vuillemin A; Laheurte C; Mansi L; Royer B; Pivot X; Borg C; Adotevi O
J Immunother; 2014 Jan; 37(1):51-4. PubMed ID: 24316556
[TBL] [Abstract][Full Text] [Related]
8. Oscillatory mTOR inhibition and Treg increase in kidney transplantation.
Sabbatini M; Ruggiero G; Palatucci AT; Rubino V; Federico S; Giovazzino A; Apicella L; Santopaolo M; Matarese G; Galgani M; Terrazzano G
Clin Exp Immunol; 2015 Nov; 182(2):230-40. PubMed ID: 26077103
[TBL] [Abstract][Full Text] [Related]
9. Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.
Bendtsen MAF; Grimm D; Bauer J; Wehland M; Wise P; Magnusson NE; Infanger M; Krüger M
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28796163
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.
Thiery-Vuillemin A; Theodore C; Jacobasch L; Schmitz J; Papandreou C; Guillot A; Emmanouilides C; Slimane K; Kelkouli N; Kim S; Nguyen Tan Hon T
Clin Genitourin Cancer; 2015 Jun; 13(3):231-8. PubMed ID: 25456838
[TBL] [Abstract][Full Text] [Related]
11. Regulatory T cells, dendritic cells and neutrophils in patients with renal cell carcinoma.
Minárik I; Lašťovička J; Budinský V; Kayserová J; Spíšek R; Jarolím L; Fialová A; Babjuk M; Bartůňková J
Immunol Lett; 2013 May; 152(2):144-50. PubMed ID: 23721909
[TBL] [Abstract][Full Text] [Related]
12. Effects of interleukin-2 treatment on CD1d-restricted natural killer T cells.
Sandberg JK; Moll M
Clin Cancer Res; 2007 Jul; 13(14):4311; author reply 4311-2. PubMed ID: 17634562
[No Abstract] [Full Text] [Related]
13. Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity.
Beziaud L; Mansi L; Ravel P; Marie-Joseph EL; Laheurte C; Rangan L; Bonnefoy F; Pallandre JR; Boullerot L; Gamonet C; Vrecko S; Queiroz L; Maurina T; Mouillet G; Hon TN; Curtit E; Royer B; Gaugler B; Bayry J; Tartour E; Thiery-Vuillemin A; Pivot X; Borg C; Godet Y; Adotévi O
Cancer Res; 2016 Jul; 76(14):4100-12. PubMed ID: 27197194
[TBL] [Abstract][Full Text] [Related]
14. Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor.
Santoni M; Berardi R; Amantini C; Burattini L; Santini D; Santoni G; Cascinu S
Int J Cancer; 2014 Jun; 134(12):2772-7. PubMed ID: 24114790
[TBL] [Abstract][Full Text] [Related]
15. [Spontaneous Remission of Everolimus-Induced Interstitial Lung Disease in Metastatic Renal Cell Carcinoma : An Autopsy Case Report].
Kurokawa M; Naito S; Ichiyanagi O; Kabasawa T; Kurota Y; Sakurai T; Nishida H; Kawazoe H; Kato T; Nagaoka A; Yamakawa M; Tsuchiya N
Hinyokika Kiyo; 2017 Sep; 63(9):377-380. PubMed ID: 28992668
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Urbanowitz G; Berg WJ; Kay A; Lebwohl D; Ravaud A;
Lancet; 2008 Aug; 372(9637):449-56. PubMed ID: 18653228
[TBL] [Abstract][Full Text] [Related]
17. Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.
Jebali M; Elaidi R; Brizard M; Fouque J; Takouchop C; Sabatier B; Oudard S; Medioni J
BMC Cancer; 2017 Jan; 17(1):27. PubMed ID: 28061764
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy.
Luan FL; Hojo M; Maluccio M; Yamaji K; Suthanthiran M
Transplantation; 2002 May; 73(10):1565-72. PubMed ID: 12042641
[TBL] [Abstract][Full Text] [Related]
19. A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer.
Lolli C; Gallà V; Schepisi G; Barone D; Burgio SL; Maugeri A; Vertogen B; Amadori D; De Giorgi U
Oncologist; 2017 Jul; 22(7):784-e74. PubMed ID: 28546463
[TBL] [Abstract][Full Text] [Related]
20. Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T.
Tsimafeyeu I; Snegovoy A; Varlamov S; Safina S; Varlamov I; Gurina L; Manzuk L
Target Oncol; 2015 Sep; 10(3):423-7. PubMed ID: 25466382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
